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Abstract The pentaspan protein CD133 (Prominin-1) is
part of the signature of tumour-initiating cells for various
cancer entities. The aim of the present study was to inves-
tigate the impact of ectopic CD133 expression on tumouri-
genic properties of otherwise CD133-negative, non-
tumourigenic cells in vitro and in vivo. CD133 was stably
transfected into human embryonic kidney 293 (HEK293)
which was then sorted for the expression of CD133. The
effects of CD133 on cell proliferation were assessed upon
standard cell counting of sorted cells at various time points.
Severe combined immunodeficient (SCID) mice (n030)
were injected with HEK293 CD133high and CD133low trans-
fectants (5×103, 1×105, or 5×106 cells per injection). The
expression of CD133, Ki67, CD44s, CD44v6, and EpCAM
was analysed upon immunohistochemical staining of cryo-
sections with specific antibodies. In vitro, ectopic expression
of CD133 did influence neither cell proliferation nor cell cycle
distribution of otherwise CD133-negative HEK293 cells.
However, CD133high cells generated tumours in vivo in SCID
mice with at least 1,000-fold increased frequency compared to
CD133low cells. Tumour load was also significantly increased
in CD133high cells as compared to those tumours formed by
high numbers of CD133low cells. Immunohistochemistry
stainings disclosed no changes in Ki67, CD44s, CD44v6, or
EpCAM once tumours were formed by either cell type.
CD133 induces tumour-initiating properties in HEK293 cells
in vivo and is potentially involved in the regulation of tumour-
igenicity. Future research will aim at the elucidation of mo-
lecular mechanisms of CD133-induced tumourigenicity.
Keywords CD133 . HEK293 . Tumourigenic potential .
Mouse model
Martin Canis and Axel Lechner have equally contributed.
M. Canis :A. Lechner : B. Mack : P. Zengel :O. Gires
Department of Otorhinolaryngology,
Head and Neck Surgery,
Grosshadern Medical Centre,










Institute of Medical Informatics,
Biometry, and Epidemiology,
Ludwig–Maximilians University of Munich,
Munich, Germany
U. Koehler









Head and Neck Research Department,
Ludwig–Maximilians University of Munich,
Marchioninistr. 15,
81377 Munich, Germany
Tumor Biol. (2013) 34:437–443
DOI 10.1007/s13277-012-0568-z
Introduction
Accumulating data demonstrate that malignant tumours are
structured hierarchically, and their formation is driven by a
small sub-population of tumour-initiating cells (TICs). These
cells show self-renewal capacity and may be responsible for
tumour progression and metastasis [1]. TICs, also termed as
cancer-stem cells, were first identified in human acute mye-
loid leukaemia and represented cells expressing the cell sur-
face markers CD34high and CD38low [2, 3]. Similar to the
haematopoetic system, epithelial linings undergo continuous
turnover and are hierarchically organised according to a stem
cell system [4]. In 2004, CD133high cells were isolated from
the human brain tumours, which showed tumour-initiating
capacity and recapitulated the original phenotype of the tu-
mour of origin after serial transplantation in vivo [5]. CD 133
is a ∼120-kDa glycoprotein with an N-terminal extracellular
domain, two large extracellular loops, and an intracellular C-
terminus [6]. In vitro experiments revealed that the expression
of CD133 in cell lines is associated with enhanced clonoge-
nicity and tumourigenicity [7, 8]. CD133 thus obtained great
attention, owing to its high expression in the form of a hyper-
glycosylated variant in TICs of various origins [1, 9, 10]. Very
recently, a role for CD133 and the Src kinase in the regulation
of tumour initiating properties and the transition from
an epithelial to a mesenchymal phenotype of head and
neck carcinoma cells has been demonstrated [11]. Beside
CD133, markers such as CD24, EpCAM, CD166, Lgr5,
CD47, and ALDH have been discussed and serve for the
selection of tumour-initiating cells [12]. The aim of the present
study was to investigate the impact of ectopic CD133 expres-
sion on tumourigenic properties of otherwise CD133-
negative, non-tumourigenic cells in vitro and in vivo. De novo
expression of CD133 in human embryonic kidney 293
(HEK293) cells conferred tumour-initiating capacity to these
otherwise CD133-negative cells, strongly suggesting that
CD133 actively contributes to the TIC phenotype of malig-
nant cells.
Materials and methods
Cell lines and cell counting
HEK293 cells [13] and CaCo-2 colon carcinoma cells were
purchased from ATCC. CaCo-2 cells express CD133 endog-
enously and therefore served as a positive control. HEK293
transfectants were generated upon magnet-assisted transfec-
tion (MaTra, Iba, Göttingen, Germany) of the pCR3.1-uni
vector, in which the cDNA for CD133 was introduced by
conventional cloning. The selection of stable transfectants
was achieved with standard DMEM medium supplemented
with G418 (Calbiochem, Merck GmbH, Schwalbach,
Germany). Stable transfectants were sorted for their
CD133 expression profile in a FACSAria II device (BD
Biosciences, Heidelberg, Germany). Sorted cells were plat-
ed in 35-mm dishes at different densities. Cell numbers were
assessed at different time points upon trypan blue exclusion
assay in Neubauer counting chambers.
Immunoblot and PNGase F treatment
Cells were lysed in 50 μl lysis buffer (1 % Triton in
TBS), and protein amounts were assessed with the
BCA™ Protein Assay Kit (Pierce, Thermo Scientific,
Rockford, IL, USA). Lysates from CD133high and CaCo
cells were treated with PNGase F to deglycosylate pro-
teins. PNGase F treatment (New England Biolabs,
P0704S) of cell supernatants was conducted as recom-
mended by the manufacturer.
Protein lysate (50 μg) was mixed with SDS-PAGE load-
ing buffer (25 mM TrisHCl, pH 7, 5 % glycerin, 1 % SDS,
2 % beta-mercaptoethanol, bromphenol blue). The proteins
were separated by SDS-PAGE, transferred onto PVDF
membranes (Millipore, Bedford, MA, USA), and detected
using specific antibodies in combination with horseradish
peroxidase-conjugated secondary antibodies and the en-
hanced chemiluminescence reagent (Amersham Bio-
sciences, Freiburg, Germany). Antibodies used are
AC133 (Miltenyi, Bergisch Gladbach, Germany),
CD133 (Cell Signalling, Danvers, MA, USA), AC133
and CD133 which are two different clones for the same
molecule, Ki67 (Dako, Hamburg, Germany), splice var-
iant of CD44s (BD Pharmingen, Heidelberg, Germany),
CD44v6 (Novocastra, Newcastle upon Tyne, UK),
EpCAM (HO.3) [14] (kind gift of Dr. P. Ruf, Trion
Research, Munich Germany), and actin (Santa Cruz
Biotechnology Inc., Santa Cruz, CA, USA).
Flow cytometry
Cells were stained with a 1:50 dilution of an anti-
CD133 antibody (AC133, Miltenyi) or an isotype con-
trol (IgG1, Dako) for 15 min on ice, washed three times
in PBS supplemented with 3 % of foetal calf serum
(FCS), and stained with fluorescein isothiocyanate-
conjugated secondary antibody. Measurement of cell
surface expression of CD133 was performed in a FACS-
Calibur device (BD Pharmingen).
Semi-quantitative RT-PCR
Total RNA from cell lines was isolated using the High Pure
RNA Isolation Kit (Macherey & Nagel, Dueren, Germany),
and the cDNAwas generated using the reverse transcription
system (Promega, Madison, WI, USA) according to the
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manufacturer's instructions. Semi-quantitative PCR analysis
for the expression of CD133 and GAPDH (95 °C for 30 s,
annealing for 30 s, 72 °C for 30 s) was conducted with
specific primers: for CD133 (194 bp), 5′-tggggctgctgtttat
tattct-3′ and 5′-tgccacaaaaccatagaagatg-3′, while for
GAPDH (258 bp), FW: 5′-tgtcgctgttgaagtcagaggaga-3′ and
BW: 5′-agaacatcatccctgcctctactg-3′.
Xenotransplantation model
Six-week-old severe combined immunodeficient (SCID)
male mice (n030) were injected with HEK293 CD133high
and CD133low transfectants subcutaneously into the right
and left flanks of the same mouse, respectively (5×103,
1×105, or 5×106 cells per injection in 100 μl medium and
100 μl Matrigel, BD Pharmingen). All experiments were
performed according to Bavarian state regulations for ani-
mal experimentation and were approved by the responsible
authorities, the District Government of Upper Bavaria (Ani-
mal licence no.: 55.2-1-54-2531-101-07). After 21–36 days,
the mice were killed in a CO2 gas environment. Subsequently,
all tumours were dissected and removed, weighed, and imme-
diately embedded in Tissue-Tek before cryopreservation in
liquid nitrogen and storage at −20 °C. Immunohistochemistry
of the mouse samples was performed as described for human
materials. Human antigens were detected with CD133 pure
(Miltenyi, dilution 1:100), CD44v6 (Novocastra, dilution
1:300), CD44s (BD Pharmingen, dilution 1:4,000), and
Ki67 (Dako, dilution 1:800) antibodies. For isotype control,
mouse IgG1 (Dako) antibody was used, while mouse IgG2b
antibody (Sigma) served as negative control for CD44s.
Immunodetection of primary antibodies was carried out using
biotinylated anti-mouse antibody coupled with peroxidase-
labelled avidin–biotin complex (Vector Lab. Inc., Burlingame,
CA, USA).
Results
CD133 expression in vitro in HEK293 cells
In order to address a putative role of CD133 in the regula-
tion of the oncogenic potential of cells, HEK293 cells were
stably transfected with an expression plasmid for CD133.
HEK293 clones used under the experimental conditions
applied herein possess only very low tumourigenic capacity
and hardly generate tumours within a time span of 3 weeks
[15]. Bulk cultures of stable transfectants were analysed for
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Fig. 1 CD133 expression in HEK293 cells. a HEK293 cells were
stably transfected with an expression plasmid for CD133. Flow cytom-
etry analysis revealed mixed populations of CD113low and CD133high
cells within single stable transfectants. Cells were sorted to obtain pure
populations with mean fluorescence intensities ratios of CD133low0
1.6±0.07 and CD133high039±6.2. b CD133 mRNA RNA levels were
assessed by standard RT-PCR in CD113low and CD133high cells.
GAPDH mRNA levels served as control. c CD133 protein levels were
assessed upon immunoblotting with two independent antibodies from
two different clones for the same molecule (CS Cell Signaling, MY
Miltenyi). Colon carcinoma cells CaCo, which endogeneously express
CD133, were assessed similarly as control. Actin was used as a loading
control (left panels). Lysates from CD133high and CaCo cells were
treated with PNGase to deglycosylate proteins. Thereafter, lysates of
untreated cells and treated lysates were separated in a 10 % SDS-PAGE
and CD133 detected with specific antibody (MY, right panels). d Equal
cell numbers (3×105 cells) of HEK293 CD113low and CD133high cells
were plated, and the cell numbers were assessed at the indicated time
points. Shown are the mean and standard deviations of the three
independent experiments
b
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with specific antibodies. An example of one bulk culture is
shown in Fig. 1a. Two spontaneously occurring sub-
populations were observed which differed significantly in
their expression profile of CD133. CD133low and CD133high
cells were separated upon FACS sorting before every xeno-
transplantation, yielding two sub-populations with CD133
average mean fluorescence intensity ratios (CD133/con-
trols) of 1.6±0.07 and 39±6.2, respectively (Fig. 1a, lower
panels). Expression levels of CD133 mRNA and protein
were additionally assessed upon RT-PCR and immunoblot-
ting of the resulting cell populations (Fig. 1b, c). Even
though CD133 expression was below the detection limit in
CD133low cells in immunoblot experiments, single cells
were positive for CD133 as observed in the immunocyto-
chemical stainings (data not shown). In CD133high cells,
CD133 protein expression was comparable to the endoge-
nous levels seen in colon carcinoma cell line CaCo-2 inde-
pendently of the primary anti-CD133 antibody used for
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Fig. 2 Measurement of the
tumourigenic potential of
CD113low and CD133high cells
in vivo. a SCID mice were
inoculated subcutaneously with
increased amounts of CD113low
and CD133high cells in the left
and right flank, respectively.
After 21 to 36 days, the animals
were killed, and the tumour
load in grams was monitored.
The results shown represent
two experiments with five mice
each (n010). Black and red
diamonds give the tumorload in
regard of numbers of injected
cells. b Tumours generated by
CD113low and CD133high cells
are exemplified before (left and
upper right images) and after
preparation (lower right image).
The blood vessels supplying the
tumours are marked with
arrows in the upper right panel.
c Tumour formation frequency
of CD133low and CD133high
HEK293 cells. SCID mice
(n010 in two independent
experiments) have been
inoculated with the indicated
cell numbers and tumour
formation assessed over a time
period of 21–36 days. Shown
are frequencies of tumour
formation: grey bars represent
no formation of tumours, while
black bars represent tumour
formation independently of the
tumour size and weight
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detection (Fig. 1c). Ectopically expressed CD133 migrated in
SDS-PAGE as two protein bands with an apparent molecular
weight of 130 and 110 kDa (Fig. 1c). After the treatment of the
cell lysates with glycosidase, CD133 derived from HEK293,
CD133high, and from CaCo-2 cells shifted to a protein with an
apparent molecular weight of approximately 83 kDa (Fig. 1c,
right panels), thus suggesting that higher molecular weight
species of CD133 resulted from post-translational glycosyla-
tion and represent closely the variant preferentially expressed in
TICs [9]. Next, the proliferation capacity of both cell clones
was assessed over a time period of 4 days. CD133low and
CD133high cells were plated at equal cell numbers and counted
daily. Both cell cultures grew exponentially, with CD133low
cells displaying minimally increased cell numbers as compared
to CD133high cells; however, there was no significant difference
(Fig. 1d). These findings were corroborated by analyses of cell
cycle distributions of both cell sub-populations. After re-
addition of serum factors to serum-starved CD133low and
CD133high cells (0.1%FCS), CD133low cells displayed slightly
enhanced percentages of cells in S phase compared to
CD133high cells (data not shown).
Tumour-initiation capacity of HEK293 cell clones in vivo
We next tested the impact of CD133 expression on the ability
of HEK293 cells to form tumours in vivo in immunocompro-
mised SCID mice. Increasing numbers of CD133low and
CD133high cells (5×103, 1×105, and 5×106 cells per injec-
tion) were injected with Matrigel (1:1) in the left and right
flank of the same SCID mouse (n010 per cell numbers).
Tumour formation was recorded as the weight of resulting
tumours at the site of injection. Tumours were allowed to
generate within a time period of 21–36 days. CD133low cells
generated very small tumours in two out of the 30 injections
(7%) and only at the highest concentrations of 5×106 cells per
injection (Fig. 2a, c). CD133high cells generated tumours in 29
out of the 30 injections (97 %) (Fig. 2c) and displayed a dose
dependency with respect to the tumour mass (Fig. 2a). At
concentrations of 5×103 cells, CD133high cells grew to
tumours of sizes comparable to those generated by 5×106
CD133low cells (Fig. 2a). From these results, we deduced that
CD133high cells are leastwise a 1,000-fold enriched in
tumourigenic cells compared with their CD133low counter-
parts. At highest concentrations of 5×106 CD133high cells,
tumours had maximal weights of 1.4 g, representing up to 7 %
of the total body weight of the animal. Typically, tumours
originating from the CD133high cells were connected to blood
vessels, which were almost entirely missing on the opposite
side, which had been inoculated with CD133low cells (Fig. 2b,
arrows). Accordingly, CD133high tumour specimens were well
supplied with blood (see example in Fig. 2b, right panels).
Tumour samples of both CD133high and CD133low cells
were cryopreserved, processed to sections, and stained with





























analysis of CD133, Ki67,
CD44s, CD44v6, and EpCAM
in HEK293-derived tumours. a
Sections of cryopreserved sam-
ples of tumours derived from
CD113low and CD133high cells
inoculated in SCID mice were
stained with CD133- and Ki67-
specific antibodies and with an
isotype-matched antibody for
CD133 as a control. b Same as
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proliferation, and an isotype control antibody. CD133high-
derived tumours (n029) were characterised by a homoge-
neous and high CD133 expression and by a high prolifera-
tion rate (exemplified in Fig. 3a, upper panels). In
CD133low-derived tumours (n02), only single cells
expressed CD133, reflecting the original expression pattern
of CD133 determined in vitro, while proliferation was com-
parable to CD133high-derived samples. Additional trans-
membrane proteins such as CD44 and EpCAM have been
associated with tumour-initiating frequency and are abun-
dantly expressed in TICs of numerous tumour entities [1,
16]. In order to assess the potential differences in these
molecules, CD133high- and CD133low-derived tumours were
stained for the standard CD44s, CD44v6, and for EpCAM.
Both tumour samples similarly expressed CD44s and did
not display any reactivity for CD44v6 and EpCAM
(Fig. 3b). Hence, differences in tumour formation are not
due to the variations in the expression of CD44 or EpCAM.
Discussion
The actual function of CD133 is just emerging, and until
recently, an implication in the determination of haemato-
poietic stem cells (HSCs) and neuroepithelial progenitors
was the only known role [17]. Most recent publications
reported on the association of CD133 with Src kinase [18],
which is instrumental in tumour initiation and during transi-
tion from an epithelial to a mesenchymal phenotype (EMT)
[11]. In the present study, we demonstrate a potential for
CD133 to induce a tumour-initiating phenotype in cells
endowed with very low tumourigenicity. Tumour seeding
frequency in CD133high HEK293 cells was leastwise 1,000-
fold higher than in CD133low counterparts, although the cel-
lular and morphologic features of these cells were indistin-
guishable in vitro. Especially, no traits of EMTwere observed
in these cells, including unchanged expression levels of typ-
ical EMT markers such as vimentin, N-cadherin, or smooth
muscle actin (data not shown). This lack of difference between
CD133high and CD133low cells in vitro is perfectly in accor-
dance with previous reports on the knock-down of CD133 in
colon carcinoma CaCo-2 cells, which was likewise without
any measurable outcome in vitro [19, 20]. From their results,
Horst et al. [19, 20] deduced a lack of function for CD133 in
the regulation or induction of a TIC phenotype in vitro. The
impact of CD133 on the tumour seeding capacity however
suggests that it is important for the survival and/or regulation
of tumour-seeding cells in the in vivo context. For example,
anchorage-independent growth and/or communication with
the microenvironment could account for differences between
results from in vitro and in vivo studies. An involvement of
CD133 in the cell-to-cell communication of HSCs and mes-
enchymal stem cells (MSCs) has been reported [21].
Migratory HSCs display a polarised localisation of CD133
at a rear part of the cell, a structure termed uropod, which is
uplifted and does not contact the layer of MSCs beneath.
Upon contact of the uropod with MSCs, HSCs become more
sessile and cease migration [21]. Potential ligands of CD133
on MSCs or other cell types of the microenvironment have as
yet not been explored, although they appear of great interest
for the understanding of CD133's role in the communication
of stem cells with their niche. Similar to HSCs, CD133 might
serve tumourigenic cells as a means of contact and commu-
nication with the microenvironment in vivo, thus providing
them with the capacity to interact and engraft. Accordingly,
CD133+/CD24+ marked clonogenic TICs derived from single
colon carcinoma cells in spheroid cultures or limiting dilutions
[22]. CD133+/CD24+ cells possessed a multilineage differen-
tiation potential, both in vitro and in vivo, while CD133− cells
did not. Interestingly, stromal cells in tumours generated upon
xenotransplantation of CD133+/CD24+ cells were derived
from the host and did not originate from CD133+/CD24+
tumour cells, hence indicating that CD133 might also be
required for the proper communication of tumour cells and
cells of the host's microenvironment [22].
In summary, CD133 has the potential to induce a tumour-
initiating phenotype in low tumourigenic HEK293 cells in vivo.
Since these results are descriptive only, future research will aim
at the elucidation of molecular mechanisms of CD133-induced
tumourigenicity, its putative role in the formation of metastases,
which could be linked to interactions with Src kinase, and
potentially pinpoint novel therapeutic intervention options.
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